BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 15699390)

  • 1. Thymus changes in anti-MuSK-positive and -negative myasthenia gravis.
    Lauriola L; Ranelletti F; Maggiano N; Guerriero M; Punzi C; Marsili F; Bartoccioni E; Evoli A
    Neurology; 2005 Feb; 64(3):536-8. PubMed ID: 15699390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of immunopathological features of AChR/MuSK autoantibody-negative myasthenia gravis.
    Hayashi A; Shiono H; Ohta M; Ohta K; Okumura M; Sawa Y
    J Neuroimmunol; 2007 Sep; 189(1-2):163-8. PubMed ID: 17706794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG.
    Leite MI; Ströbel P; Jones M; Micklem K; Moritz R; Gold R; Niks EH; Berrih-Aknin S; Scaravilli F; Canelhas A; Marx A; Newsom-Davis J; Willcox N; Vincent A
    Ann Neurol; 2005 Mar; 57(3):444-8. PubMed ID: 15732104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis.
    Evoli A; Tonali PA; Padua L; Monaco ML; Scuderi F; Batocchi AP; Marino M; Bartoccioni E
    Brain; 2003 Oct; 126(Pt 10):2304-11. PubMed ID: 12821509
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive value of the presence of different antibodies and thymus pathology to the clinical outcome in patients with generalized myasthenia gravis.
    Nikolic A; Djukic P; Basta I; Hajdukovic Lj; Stojanovic VR; Stevic Z; Nikolic D; Bozic V; Lavrnic S; Lavrnic D
    Clin Neurol Neurosurg; 2013 Apr; 115(4):432-7. PubMed ID: 22770539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dropped head syndrome as prominent clinical feature in MuSK-positive Myasthenia Gravis with thymus hyperplasia.
    Spengos K; Vassilopoulou S; Papadimas G; Tsivgoulis G; Karandreas N; Zambelis T; Manta P
    Neuromuscul Disord; 2008 Feb; 18(2):175-7. PubMed ID: 18053719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positive myasthenia gravis.
    Shiraishi H; Motomura M; Yoshimura T; Fukudome T; Fukuda T; Nakao Y; Tsujihata M; Vincent A; Eguchi K
    Ann Neurol; 2005 Feb; 57(2):289-93. PubMed ID: 15668981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymus histology and concomitant autoimmune diseases in Japanese patients with muscle-specific receptor tyrosine kinase-antibody-positive myasthenia gravis.
    Nakata R; Motomura M; Masuda T; Shiraishi H; Tokuda M; Fukuda T; Ando T; Yoshimura T; Tsujihata M; Kawakami A
    Eur J Neurol; 2013 Sep; 20(9):1272-6. PubMed ID: 23679930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MRI and clinical studies of facial and bulbar muscle involvement in MuSK antibody-associated myasthenia gravis.
    Farrugia ME; Robson MD; Clover L; Anslow P; Newsom-Davis J; Kennett R; Hilton-Jones D; Matthews PM; Vincent A
    Brain; 2006 Jun; 129(Pt 6):1481-92. PubMed ID: 16672291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical comparison of anti-MuSK- vs anti-AChR-positive and seronegative myasthenia gravis.
    Deymeer F; Gungor-Tuncer O; Yilmaz V; Parman Y; Serdaroglu P; Ozdemir C; Vincent A; Saruhan-Direskeneli G
    Neurology; 2007 Feb; 68(8):609-11. PubMed ID: 17310034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MuSK antibody-positive, seronegative myasthenia gravis in Korea.
    Lee JY; Sung JJ; Cho JY; Oh DH; Kim HJ; Park JH; Lee KW; Choi YC; Vincent A
    J Clin Neurosci; 2006 Apr; 13(3):353-5. PubMed ID: 16546389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Myasthenia gravis patients with anti-MuSK antibodies.
    Zagar M; Vranjes D; Sostarko M; Vogrinc Z; Bilić E; Trbojević Cepe M
    Coll Antropol; 2009 Dec; 33(4):1151-4. PubMed ID: 20102061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complete stable remission and autoantibody specificity in myasthenia gravis.
    Baggi F; Andreetta F; Maggi L; Confalonieri P; Morandi L; Salerno F; Bernasconi P; Montomoli C; Barberis M; Mantegazza R; Antozzi C
    Neurology; 2013 Jan; 80(2):188-95. PubMed ID: 23255823
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The auto-antigen repertoire in myasthenia gravis.
    Vrolix K; Fraussen J; Molenaar PC; Losen M; Somers V; Stinissen P; De Baets MH; Martínez-Martínez P
    Autoimmunity; 2010 Aug; 43(5-6):380-400. PubMed ID: 20380581
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients.
    Zhou L; McConville J; Chaudhry V; Adams RN; Skolasky RL; Vincent A; Drachman DB
    Muscle Nerve; 2004 Jul; 30(1):55-60. PubMed ID: 15221879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MuSK myasthenia gravis presenting with purely ocular findings.
    Caress JB; Hunt CH; Batish SD
    Arch Neurol; 2005 Jun; 62(6):1002-3. PubMed ID: 15956173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Seronegative myasthenia gravis].
    Gajdos P
    Rev Neurol (Paris); 2004 Feb; 160(2):159-62. PubMed ID: 15034472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.